Drug
inupadenant
inupadenant is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Active, not recruiting2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
active_not_recruiting267%
completed133%
Recent Activity
2 active trials
Showing 3 of 3
active_not_recruitingphase_2
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
NCT05403385
completedphase_1
New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer
NCT05117177
active_not_recruitingphase_1
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
NCT05060432
Clinical Trials (3)
Showing 3 of 3 trials
NCT05403385Phase 2
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
NCT05117177Phase 1
New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer
NCT05060432Phase 1
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3